{"brief_title": "Phase II Study of Recombinant Relaxin for Progressive Systemic Sclerosis", "brief_summary": "OBJECTIVES: I. Determine whether parenteral relaxin improves skin tightness, Raynaud's phenomenon, digital morbidity, and digital ulcers in a patient with progressive systemic sclerosis (scleroderma). II. Determine whether relaxin decreases collagen production by fibroblasts in vivo and cultured from skin biopsies.", "detailed_description": "PROTOCOL OUTLINE: This is a compassionate use study. The patient is treated with subcutaneous injections of recombinant relaxin for approximately 12 months. If clinically indicated, therapy may be extended.", "condition": "Systemic Sclerosis", "intervention_type": "Drug", "intervention_name": "relaxin", "criteria": "PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Progressive systemic sclerosis (scleroderma) - No pregnant or nursing women", "gender": "All", "minimum_age": "N/A", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00004380.xml"}